文献速递胸部肿瘤

靶向NGS检测的突变谱可预测LDCT筛查发现的肺癌患者的生存

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers.
PubMed 文献 · J Thorac Oncol · 2017-03-14

该研究对94例低剂量计算机断层扫描(LDCT)筛查发现的肺部肿瘤行靶向二代测序,分析突变与临床病理特征、生存及血浆microRNA特征分类器风险的相关性。结果发现,有和无肿瘤突变患者的5年总生存率分别为66%和100%(P=0.015);将突变状态与microRNA特征分类器风险联合,可将患者分为5年总生存率从42%到97%的三组(P<0.0001),控制分期后预后价值仍显著(P=0.02)。结论认为,肿瘤突变状态联合基于microRNA的液体活检可为LDCT筛查项目中的临床随访计划提供额外信息。

要点

  • LDCT筛查发现的肺癌中,有突变者5年OS为66%,无突变者为100%(P=0.015)。
  • 突变状态联合microRNA特征分类器可将患者分为5年OS从42%到97%的三组(P<0.0001)。
  • 控制分期后联合模型的预后价值仍显著(P=0.02)。

核心结论

  • 肿瘤突变状态联合基于microRNA的液体活检可为肺癌LDCT筛查项目中的临床随访计划提供额外信息。

研究设计与样本

  • 对94例LDCT筛查发现的肺部肿瘤行靶向二代测序,分析突变与临床病理特征、生存及血浆microRNA特征分类器风险的相关性。

主要发现

  • 筛查系列中观察到的突变谱和频率与公共数据集相似,但检测到更多无驱动基因突变的肿瘤。
  • 有和无肿瘤突变患者的5年总生存率分别为66%和100%(P=0.015)。
  • 将突变状态与microRNA特征分类器风险联合,患者被分为5年总生存率从42%到97%的三组(P<0.0001),控制分期后预后价值仍显著(P=0.02)。

关键数值与推荐

  • 有肿瘤突变者5年OS为66%,无肿瘤突变者为100%(P=0.015)。
  • 突变状态联合microRNA特征分类器风险分组后,三组5年OS范围42%至97%(P<0.0001),控制分期后P=0.02。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The issue of overdiagnosis in low-dose computed tomography (LDCT) screening trials could be addressed by the development of complementary biomarkers able to improve detection of aggressive disease. The mutation profile of LDCT screening-detected lung tumors is currently unknown. METHODS: Targeted next-generation sequencing was performed on 94 LDCT screening-detected lung tumors. Associations with clinicopathologic features, survival, and the risk profile of a plasma microRNA signature classifier were analyzed. RESULTS: The mutational spectrum and frequency observed in screening series was similar to that reported in public data sets, although a larger number of tumors without mutations in driver genes was detected. The 5-year overall survival (OS) rates of patients with and without mutations in the tumors were 66% and 100%, respectively (p = 0.015). By combining the mutational status with the microRNA signature classifier risk profile, patients were stratified into three groups with 5-year OS rates ranging from 42% to 97% (p < 0.0001) and the prognostic value was significant after controlling for stage (p = 0.02). CONCLUSION: Tumor mutational status along with a microRNA-based liquid biopsy can provide additional information in planning clinical follow-up in lung cancer LDCT screening programs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Verri C, Borzi C, Holscher T, et al. Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers. J Thorac Oncol. 2017. PMID: 28302568. doi:10.1016/j.jtho.2017.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。